188 related articles for article (PubMed ID: 16540518)
1. The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment.
Helldén A; Lycke J; Vander T; Svensson JO; Odar-Cederlöf I; Ståhle L
J Antimicrob Chemother; 2006 May; 57(5):945-9. PubMed ID: 16540518
[TBL] [Abstract][Full Text] [Related]
2. An unexpectedly high occurrence of aciclovir-induced neuropsychiatric symptoms in patients treated for herpesvirus CNS infection: a prospective observational study.
Lindström J; Helldén A; Lycke J; Grahn A; Studahl M
J Antimicrob Chemother; 2019 Dec; 74(12):3565-3572. PubMed ID: 31504577
[TBL] [Abstract][Full Text] [Related]
3. Aciclovir-induced neurotoxicity: Utility of CSF and serum CMMG levels in diagnosis.
Berry L; Venkatesan P
J Clin Virol; 2014 Dec; 61(4):608-10. PubMed ID: 25440915
[TBL] [Abstract][Full Text] [Related]
4. High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: an observational study.
Helldén A; Odar-Cederlöf I; Diener P; Barkholt L; Medin C; Svensson JO; Säwe J; Ståhle L
Nephrol Dial Transplant; 2003 Jun; 18(6):1135-41. PubMed ID: 12748346
[TBL] [Abstract][Full Text] [Related]
5. [Risk of CNS adverse effects of aciclovir and valaciclovir. Watch the renal function in treatment of herpes simplex and herpes zoster].
Helldén A; Bergman U; Dwyer R; Medin C; Molanaei H; Ståhle L; Thylén P; Odar-Cederlöf I
Lakartidningen; 2007 Jun 13-26; 104(24-25):1916-20. PubMed ID: 17674672
[No Abstract] [Full Text] [Related]
6. Valaciclovir: a review of its use in the management of herpes zoster.
Ormrod D; Goa K
Drugs; 2000 Jun; 59(6):1317-40. PubMed ID: 10882165
[TBL] [Abstract][Full Text] [Related]
7. Aciclovir and valaciclovir neurotoxicity in patients with renal failure.
Almond MK
Nephrol Dial Transplant; 2003 Dec; 18(12):2680; author reply 2680-1. PubMed ID: 14605302
[No Abstract] [Full Text] [Related]
8. Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness.
Simon MW; Fish DN; Deeter RG
Drugs R D; 2002; 3(6):365-73. PubMed ID: 12516939
[TBL] [Abstract][Full Text] [Related]
9. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections.
Perry CM; Faulds D
Drugs; 1996 Nov; 52(5):754-72. PubMed ID: 9118821
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects.
Gimenez F; Foeillet E; Bourdon O; Weller S; Garret C; Bidault R; Singlas E
Clin Pharmacokinet; 2004; 43(10):685-92. PubMed ID: 15244498
[TBL] [Abstract][Full Text] [Related]
11. Aciclovir and its l-valyl ester, valaciclovir.
Smiley ML; Murray A
Curr Probl Dermatol; 1996; 24():209-18. PubMed ID: 8743272
[No Abstract] [Full Text] [Related]
12. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group.
Bodsworth NJ; Crooks RJ; Borelli S; Vejlsgaard G; Paavonen J; Worm AM; Uexkull N; Esmann J; Strand A; Ingamells AJ; Gibb A
Genitourin Med; 1997 Apr; 73(2):110-6. PubMed ID: 9215092
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of valaciclovir.
MacDougall C; Guglielmo BJ
J Antimicrob Chemother; 2004 Jun; 53(6):899-901. PubMed ID: 15140857
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function.
Smith JP; Weller S; Johnson B; Nicotera J; Luther JM; Haas DW
Antimicrob Agents Chemother; 2010 Mar; 54(3):1146-51. PubMed ID: 20038622
[TBL] [Abstract][Full Text] [Related]
15. Development, evaluation and application of an isocratic high-performance liquid chromatography (HPLC) assay for the simultaneous determination of aciclovir and its metabolite 9-carboxymethoxymethylguanine in human serum and cerebrospinal fluid.
Darville JM; Lovering AM; MacGowan AP
Int J Antimicrob Agents; 2007 Jul; 30(1):30-3. PubMed ID: 17428641
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of the efficacy and safety of valaciclovir versus acyclovir in the treatment of herpes zoster.
Lin WR; Lin HH; Lee SS; Tsai HC; Huang CK; Wann SR; Chen YS; Chiang SC; Yen MY; Liu YC
J Microbiol Immunol Infect; 2001 Jun; 34(2):138-42. PubMed ID: 11456360
[TBL] [Abstract][Full Text] [Related]
17. Lack of interaction between valaciclovir, the L-valyl ester of aciclovir, and digoxin.
Soul-Lawton JH; Weatherley BC; Posner J; Layton G; Peck RW
Br J Clin Pharmacol; 1998 Jan; 45(1):87-9. PubMed ID: 9489600
[TBL] [Abstract][Full Text] [Related]
18. [Neurotoxicity after the first dose of oral administration of valaciclovir in a female hemodialyzed patient].
Saurina A; Ramírez de Arellano M; de las Cuevas X
Nefrologia; 2002; 22(1):83-4. PubMed ID: 11987691
[No Abstract] [Full Text] [Related]
19. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials.
Conant MA; Schacker TW; Murphy RL; Gold J; Crutchfield LT; Crooks RJ;
Int J STD AIDS; 2002 Jan; 13(1):12-21. PubMed ID: 11802924
[TBL] [Abstract][Full Text] [Related]
20. Aciclovir-induced neurotoxicity.
Vonberg FW; Dawson A; Scott G; Davies N
Pract Neurol; 2023 Apr; 23(2):157-159. PubMed ID: 36601749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
